strong gate
matt mindset ew report better expect result easili clear
consensu estim give manag enough confid guid investor
toward high end revenu rang given analyst
meet addit due better revenu expect benefit tax
reform rais ep guidanc rang
prior guid consensu midpoint encourag
momentum busi think thesi begin play
pleas see upgrad outlook note titl stabl fundament
link rais estim near high end rang
increas forward estim account better tavr growth lower tax
rate pt increas base new ep prior
pt base prior ep would buyer
ew see number de-risk note ew histori guid
conserv believ potenti upsid guidanc
number excit program expect blossom
think growth could buoy mitral tricuspid program
addit think market begin anticip excit year data
program cardioband pascal cardiaq harpoon discuss potenti
early-tavr unload focus sever asymptomat moder
respect final like near-term catalyst includ plan launch
centera ultra ew start us trial centera year well
ew quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight remain posit long-
term prospect tavr market think ew
done good job execut clinic initi
commerci roll-out sapien product delay
launch lotu tavr product also
support ow thesi
increas tavr market penetr high
extrem risk popul rapid expans
tavr intermedi risk patient firm price
us ou limit inroads/market share
gain competitor addit indic
upsid mitral
slowdown tavr on-label popul
pushback surgeon intermedi risk
increas competit ou price pressur
capac reimburs limit tavr use
intermediate/low risk mitral market fail
pipelin updat risk data expect
ew anticip receiv ce mark sapien ultra system sometim
remind system add taller outer skirt expect improv
valv perform us launch anticip late year ew also expect
receiv ce mark centera valv system sometim februari
system strong initi clinic result like price premium self-
expand valv europ us pivot trial launch sometim year
previous disclos ew complet enrol low risk
patient trial data like disclos fda approv like
receiv later year early-tavr trial asymptomat patient
sever aortic stenosi continu enrol
us result especi strong growth lower volum
us tavr revenu growth y/i ew estim us procedur
growth in-lin growth rate growth driven strong therapi uptak
across center growth rate particularli strong lower volum hospit
outsid us underli tavr revenu growth procedur europ
grew double-digit sale recov interrupt last year growth
european market lower penetr continu outpac matur market
japan fastest grow region quarter sapien uptak continu
center continu becom qualifi use therapi ew see market
one significantli under-penetrated
give initi guidanc investor confer ew
estim revenu higher end rang vs con
segment ew expect higher end prior revenu rang
includ thvt revenu vs con includ tmtt
product sale critic revenu rang vs con
surgic heart valv therapi revenu vs con ew also
increas ep guidanc vs con prior guidanc
ew also expect higher end previous provid rang
total revenu adjust vs con
tavr sale adjust vs con
revenu growth quarter driven dd growth uptak
tavr across region includ strong increas therapi across tavr center
us quarter also stronger perform last week year
surgic heart valv therapi revenu underli
basi vs con ew benefit strong uptak aortic valv across
geographi gain share new product critic sale grew
underli basi versu con revenu growth driven
strong uptak product portfolio especi strong growth us china
gross margin con y/i improv gm
driven product mix increas revenu tavr off-set previous
announc closur manufactur facil switzerland adjust ep beat
revenu report mm
ep
corp growthbarclay consensusy/yxfxtot hv mm except ep actualbarclay consensu barclay corp
actual result vs consensu barclay
corp growthbarclay tax dilut mm except ep actualbarclay consensu barclay corp
last updat except growth growth y/i sg inc med-tech incom expens incom tax tax rate incom ep average share dilut barclay
matthew taylor cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
